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Type 1 diabetes mellitus (T1DM) is one of the most 
common autoimmune diseases with several million 
people already affected around the globe. It is 
characterized by an absolute loss of insulin 
secretion, and results from an autoimmune process 
that destroys insulin producing ß cells within the 
pancreatic islet.1 
Diabetic ketoacidosis (DKA) at T1DM onset is 
more common in children less than 4 years of age, 
children with no family history of diabetes, those 
with low socioeconomic status, and in children with 
no medical insurance.2-6 
DKA is a metabolic crisis that can precipitate 
other life-threatening complications.7-8 In children 
and adolescents, the most notable complication is 
clinical brain edema. 9The pathophysiology of this 
life threatening event is uncertain. However, there 
is increasing evidence of cellular and metabolic 
activation during DKA and its treatment.10 
C-reactive protein (CRP) is a type I acute 
phase response protein whose synthesis in the liver 
is regulated by the pro-inflammatory cytokines IL-
6, IL-1 and TNF.1,2 Elevated plasma levels of CRP 
have been reported to be marker for endothelial cell 
dysfunction in uncomplicated, well-controlled type 
1 diabetes mellitus (TIDM).10 Hs-CRP can also be 
elevated in  trauma, surgery, burns, tissue necrosis 
and advanced cancer11and has been considered a 
marker of adverse outcome in acute coronary 
syndromes and atherosclerosis.12  
Previous studies have shown that during the 
metabolic crisis of  DKA, the pro-inflammatory 
cytokine levels (mainly IL-6) and anti-
inflammatory cytokine IL-10 levels are increased13  
in parallel with  the severity of DKA.14 IL-6 is 
mainly secreted by macrophages and 
lymphocytes.15  Increased IL-6 production has been 
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Background: Diabetic ketoacidosis (DKA) is a metabolic crisis that can 
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difference was found between both groups as regard hs-CRP and IL6 (p 
value for both <0.001).As regard time factor, (at admission and after 48 
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observed in patients with sepsis,16 non-infectious 
systemic inflammatory response syndrome (SIRS)17 
and also during  chronic inflammation and 
endothelial damage, such as in atherosclerosis.18 
The above pro-inflammatory cytokines and 
especially IL-6 induce the hepatic synthesis of 
plasma hs-CRP.19 
Hs-CRP is the measure of CRP with greater 
accuracy with a lower detection limit of 0.02 
mg/dL, which is 100 times more sensitive than the 
usual CRP measurement (lower detection limit 5 
mg/L).20  
The aim of this study was to investigate the 
role of hs-CRP in DKA children and its relation to 




This is a prospective study that involves pediatric 
patients age <15 years (upper limit of pediatric  age 
admitted to our pediatric intensive care unit (PICU) 
during the period from May 2012 to May 2013 who 
presented  to Pediatric ICU of Zagazig University 
Children2s Hospital  with diabetic ketoacidosis. 
DKA was defined as presence of hyperglycemia 
(blood glucose >200 mg/dL) with a venous pH <7.3 
and/or bicarbonate <15 mmol/L with associated 
glycosuria, ketonuria, and ketonemia. DKA was 
categorized as mild (venous pH <7.30; bicarbonate 
<15 mmol/L), moderate (pH <7.2; bicarbonate <10 
mmol/L), and severe (pH: <7.1; bicarbonate: <5 
mmol/L). 21 
The patients had no evidence of acute 
pancreatitis or acute/chronic infection. Acute 
infection was ruled out after a thorough medical 
history and clinical examination by the pediatrician 
as well as a sequential evaluation in the pediatric 
department after the admission. 
All studies were conducted in accordance with 
the guidelines approved by the local research ethics 
committee. 
Laboratory analysis 
Blood samples were drawn at 2 sessions; at 
presentation and after rehydration and resolution of 
DKA. 
Laboratory tests included blood pH, glucose levels, 
serum electrolytes, WBC count, blood and urine 
cultures. 
Samples for IL-6 and hs-CRP level were 
collected from all patients by venous puncture 
technique into Vacutainer tubes with EDTA.    
Specimens were centrifuged at 2500×g for 15 min 
at 4 °C. Plasma was used to measure the levels of 
glucose while the serum was stored at −20 °C until 
time of assay of IL-6 and hs-CRP levels. 
 The levels of serum IL-6 were measured using 
a commercial kit (AviBion Human IL-6 ELISA, 
Ani Biotech Oy Orgenium Laboratories Business 
Unit Tiilitie 3 FIN-07120 Vantaa Finland, ref 
IL06001). The level of serum hs-CRP assayed with 
the immunonephelometric method (Cobas 6000, 




The data were analyzed using SPSS, version 16. 
Quantitative variables were expressed as mean ± 
standard deviation (SD) and then compared using t 
test. Qualitative variables were expressed as 
frequency and percentage and compared using chi-
square test. Correlations were performed using the 
Pearson bivariate correlation. A p value was 
considered significant if less than 0.05.  
 
RESULTS 
Seventeen of the studied patients were males 
(56.7%). In most patients DKA resolved in 24 to 48 
hours. Mild DKA (1st group) was diagnosed in 11 
patients (36.7%) and moderate/severe DKA (2nd 
group) were present in 19 patients (63.4%). 
Demographic and clinical data were summarized in 
table I. Age of patient ,sex and BMI were not 
significantly differ between mild and 
moderate/severe DKA (p value:0.254, 0.287and 
0.167 respectively). As regard blood glucose at 
presentation it was showed non-significant 
statistical difference between both groups (p value: 
0.737), while blood urea nitrogen and PH were 
significantly differ in mild DKA than moderate 
/severe DKA (p value for both<0.001). It was 
observed that hs-CRP level showed highly 
significant increase in moderate/severe than mild 
group. Also, IL6 did the same (p value for both 
<0.001). 
As regard time factor (at admission and after 
DKA resolution) and its effect on hs-CRP and IL6, 
they did not significantly affected in mild DKA (p 
value: 0.892 and 0.251), nevertheless they showed 
highly significant statistical difference in 
moderate/severe DKA (p value for both<0.001). 
Correlation of hs-CRP with IL6 and WBCs in 
moderate /severe DKA are shown in table III. So 
hs-CRP was strongly associated with IL6 in 
moderate /severe DKA (r-0.637, P-value-0.003), 
also it is associated with leukocytosis in 
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Table 1. Demographic and laboratory data of study population. 
 
p. value t. test Moderate/ 
severe  DKA 
Mild DKA  







Sex       M 
             F 
>0.05 1.41 17.36±1.21 18.18±1.94 BMI 
>0.05 0.339 464±77 455±69 Glucose (mg/dl) 
<0.05 5.49 7.09±0.09 7.22±0.03 Ph 
<0.05 0.589 37.26±13.18 17.72±4.51 BUN (mg/dl) 
<0.05 13.31 10.3±2.79 1.29±0.72 hs-CRP (mg/dl) 
<0.05 5.53 23.68±7.64 13±2.68 IL6 (pg/ml) 
hs-CRP: high sensitivity C-reactive protein, IL6: interleukin 6, BUN: blood urea nitrogen 
 
 
Table 2. hs-CRP and IL6 among mild DKA patients before and after treatment. 
 
P value test After resolution At admission  
>0.05 1.39 1.3±0.62 1.29±0.72 hs-CRP (mg/dl) 
>0.05 1.21 14.18±2.96 13±2.68 IL6 (pg/ml) 
hs-CRP: high sensitivity C-reactive protein, IL6: interleukin 6 
 
 
Table 3. hs-CRP and IL6 among moderate/severe DKA patients before and after treatment. 
 
P value test After resolution At admission  
<0.05 9.18 4.83±1.07 10.3±2.79 hs-CRP (mg/dl) 
<0.05 6.8 16.20±4.97 23.68±7.64 IL6 (pg/ml) 
hs-CRP: high sensitivity C-reactive protein, IL6: interleukin 6 
 
 
Table 4. Correlation of hs-CRP with IL6 and WBCs in moderate /severe DKA. 
 
p-value r hs-CRP 
0.003 0.637 IL6 (pg/ml) 
0.021 0.524 WBCs 





Our results demonstrated increased hs-CRP in DKA 
patients at diagnosis in the absence of infection and 
this is in harmony with previous studies.15,22 This 
increase  is explained as follow: Insulin attenuates 
the production of the acute phase proteins (CRP and 
haptaglobin) in cell culture exposed to IL6,23also it 
has reported that hyperglycemia results in 
leukocytosis and elevation of inflammatory 
cytokines IL6, IL1B, TNF±, possibly  through 
augmented production in monocytes.24-25  
Other mechanism include hyper-
triglyceridaemia observed in DKA may be a 
contributing factor the increased levels of hs-CRP, 
IL6, IL1B and TNF±, thus insulin deficiency 
increases level of hs-CRP by direct action and  
indirect action  through its effects (hyperglycemia 
and hypertriglyceridaemia).26 
As regard leukocytosis, it was observed in our 
patients without evidence of infection. This is in 
accordance with Dalton et al,22 who found 
leukocytosis (>15,000) in 6 patients with DKA in 
absence of infection. Floud et al, 27also reported that 
leukocytosis is commonly present in DKA, even 
without infection. This finding is also in harmony 
with Stentz et al, who confirmed the presence of 
leukocytosis in hyperglycemic crises without 
obvious infection during febrile events. This could 
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be due to sympathetic stimulation that occur during 
hyperglycemia as increased sympathetic activity in 
normal subjects results in leukocytosis and 
elevation of IL6 and TNF±.23 
As regard IL6, it was increased in our patients 
at diagnosis. This also is in agreement with 
Karavanaki et al,14 and  Dalton et al,22 and  it is 
explained as IL6 is a mediator for hs-CRP and 
results in its increase.24 
As regard effect of treatment on hs-CRP and 
IL6, we observed that their serum levels were 
decreased significantly in moderate/severe DKA 
group after treatment. This is in harmony with 
Hansen et al, who report that intensive insulin 
therapy in critically ill patients has anti- 
inflammatory action through reduction of CRP, IL6 
and leukocytes so improve survival.28 These 
changes in hs-CRP and IL6 can be attributed to the 
anti-inflammatory action of insulin which has been 
suggested by Dandona et al. 29 
Our study showed that hs-CRP has positive 
correlation with IL6 and WBCs in moderate /severe 
DKA group and this is in accordance with Dalton et 
al,22 who found significant correlation between CRP 
and IL6 and  this explained as mentioned above as 
IL6 is a mediator for hs-CRP. 
 
CONCLUSION 
Our study reported that hs-CRP is increased in 
moderate/severe DKA patients along with IL6 and 
leukocytes in absence of infection. These findings 
might clarify the role of hs-CRP in DKA crises as a 
marker of severity as it increase significantly at 
diagnosis in moderate/severe DKA group and 
reduced significantly after treatment. 
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